Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0YS1U
|
||||
Former ID |
DIB018038
|
||||
Drug Name |
sparsentan
|
||||
Synonyms |
RE-021; retrophin; DARA-a (Dual Acting Receptor Antagonist of angiotension and endothelin receptors); compound 7 [PMID 15634011]
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Myocardial infarction [ICD9: 410; ICD10:I21, I22] | Phase 2 | [527366] | ||
Structure |
Download2D MOL |
||||
Formula |
C32H40N4O5S
|
||||
InChI |
InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
|
||||
InChIKey |
WRFHGDPIDHPWIQ-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Type-1 angiotensin II receptor | Target Info | Antagonist | [527799] | |
Endothelin-1 receptor | Target Info | Antagonist | [527799] | ||
KEGG Pathway | Calcium signaling pathway | ||||
cGMP-PKG signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Adrenergic signaling in cardiomyocytes | |||||
Vascular smooth muscle contraction | |||||
Renin-angiotensin system | |||||
Renin secretion | |||||
Pathways in cancerhsa04020:Calcium signaling pathway | |||||
cAMP signaling pathway | |||||
Pathways in cancer | |||||
PathWhiz Pathway | Angiotensin Metabolism | ||||
Muscle/Heart Contraction | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.